Publications

Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences

Tenna Vesterman HenriksenNoelia TarazonaAmanda FrydendahlThomas ReinertFrancisco Gimeno-ValienteJuan Antonio Carbonell-AsinsShruti SharmaDerrick RennerDina HafezDesamparados RodaMarisol HuertaSusana RosellóAnders Husted MadsenUffe S. LøvePer Vadgaard AndersenOle Thorlacius-UssingLene Hjerrild IversenKåre Andersson Gotschalck, Himanshu Sethi, Alexey AleshinAndres Cervantes and Claus Lindbjerg Andersen. Clinical cancer research DOI:  10.1158/1078-0432.CCR-21-2404

Cirkulerende tumor-DNA ved behandling af kræft

Cecilie Riis Iden, Amanda Frydendahl Boll Johansen, Nadia Øgaard, Iben Boutrup Kongsfelt, Kristian Egebjerg, Claus Lindbjerg Andersen, Morten Mau-Sørensen.Cirkulerene tumor-DNA ved behandling af kræft. Ugeskr Læger 2021;183:V02210154
https://ugeskriftet.dk/videnskab/cirkulerende-tumor-dna-ved-behandling-af-kraeft

Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival

Jakobsen A, Andersen RF, Hansen TF, Jensen LH, Faaborg L, Steffensen KD, Thomsen CB, Wen SWC. Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. Eur J Cancer. 2021 Apr 12;149:128-133. doi: 10.1016/j.ejca.2021.03.006. Epub ahead of print. PMID: 33857886.
https://www.sciencedirect.com/science/article/pii/S0959804921001544?via%3Dihub

Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer.

Tarpgaard LS, Andersen PV, Øgaard N, Demuth C, Andersen CL, Pfeiffer P. Ann Oncol. 2021 Mar 13:S0923-7534(21)00875-9. doi: 10.1016/j.annonc.2021.03.001.
https://www.sciencedirect.com/science/article/pii/S0923753421008759?via%3Dihub

The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer

Wen SWC, Andersen RF, Hansen TF, Nyhus CH, Hager H, Hilberg O, Jakobsen A. The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2021 Feb;10(2):855-865. doi: 10.21037/tlcr-20-826. PMID: 33718027; PMCID: PMC7947403.

https://tlcr.amegroups.com/article/view/48783/html

Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma

Wen SWC, Andersen RF, Petersen LMS, Hager H, Hilberg O, Jakobsen A, Hansen TF. Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma. Cancers (Basel). 2020 Dec 11;12(12):3728. doi: 10.3390/cancers12123728. PMID: 33322500; PMCID: PMC7763990.

https://www.mdpi.com/2072-6694/12/12/3728

Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion

Sarah Ø Jensen, Nadia Øgaard, Hans Jørgen Nielsen, Jesper B Bramsen, Claus L Andersen, Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion, Clinical Chemistry
https://academic.oup.com/clinchem/advance-article/doi/10.1093/clinchem/hvaa100/5847939?guestAccessKey=1be8b53c-9433-4fe6-8a23-6658a136d43f

Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations

Nygård L, Ahlborn LB, Persson GF, Chandrananda D, Langer JW, Fischer BM, Langer SW, Gabrielaite M, Kjær A, Rosenfeld N, Mouliere F, Østrup O, Vogelius IR, Bentzen SM. Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations. PLoS One. 2020 Apr 28;15(4):e0231884. doi: 10.1371/journal.pone.0231884. PMID: 32343749; PMCID: PMC7188247.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0231884


The effect of surgical trauma on circulating free DNA levels in cancer patients - implications for studies of circulating tumor DNA.

Henriksen TV, Reinert T, Christensen E, Sethi H, Birkenkamp-Demtröder K, Gögenur M, Gögenur I, Zimmermann BG; IMPROVE study group, Dyrskjøt L, Andersen CL.Mol Oncol. 2020 May 29. doi: 10.1002/1878-0261.12729. Online ahead of print.PMID: 32471011 Free article
https://pubmed.ncbi.nlm.nih.gov/32471011/?from_term=andersen-cl&from_sort=date&from_page=1&from_size=50&from_pos=1

Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer

Boysen AK, Pallisgaard N, Andersen CSA, Spindler KG. Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer. Acta Oncol. 2020 Dec;59(12):1424-1429. doi: 10.1080/0284186X.2020.1806357. Epub 2020 Aug 13. PMID: 32790489.

https://www.tandfonline.com/doi/full/10.1080/0284186X.2020.1806357

Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER)

Skougaard K, Østrup O, Guldbrandsen K, Sørensen B, Meldgaard P, Saghir Z, Gørtz P, Lonsdale MN, Frank MS, Gerke O, Rychwicka-Kielek BA, Persson G, Land LH, Schytte T, Bodtger U, Skuladottir H, Søgaard J, Nielsen SS, Rasmussen TR, Fischer BM. Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER). Clin Lung Cancer. 2020 Mar;21(2):e61-e64. doi: 10.1016/j.cllc.2019.11.002. Epub 2019 Nov 21. PMID: 31839533.

https://www.sciencedirect.com/science/article/pii/S1525730419303195?via%3Dihub

Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
Ørntoft MW, Jensen SØ, Øgaard N, Henriksen TV, Ferm L, Christensen IJ, Reinert T, Larsen OH, Nielsen HJ, Andersen CL.Int J Cancer. 2020 Dec 15. doi: 10.1002/ijc.33434. Online ahead of print.PMID: 33320961
Toward liquid biopsies in cancer treatment: application of circulating tumor DNA
Barlebo Ahlborn L, Østrup O. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA. APMIS. 2019 May;127(5):329-336. doi: 10.1111/apm.12912. Epub 2019 Feb 19. PMID: 30784124.
 
Application of cell-free DNA for genomic tumor profiling: a feasibility study
Ahlborn LB, Rohrberg KS, Gabrielaite M, Tuxen IV, Yde CW, Spanggaard I, Santoni-Rugiu E, Nielsen FC, Lassen U, Mau-Sorensen M, Østrup O. Application of cell-free DNA for genomic tumor profiling: a feasibility study. Oncotarget. 2019 Feb 15;10(14):1388-1398. doi: 10.18632/oncotarget.26642. PMID: 30858924; PMCID: PMC6402712.
 

https://www.oncotarget.com/article/26642/text/

Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

Nørøxe DS, Østrup O, Yde CW, Ahlborn LB, Nielsen FC, Michaelsen SR, Larsen VA, Skjøth-Rasmussen J, Brennum J, Hamerlik P, Poulsen HS, Lassen U. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study. Oncotarget. 2019 Jul 9;10(43):4397-4406. doi: 10.18632/oncotarget.27030. PMID: 31320993; PMCID: PMC6633897.

https://www.oncotarget.com/article/27030/text/